Exponents Ranked #1087 on the 2025 Inc. 5000
SAN DIEGO–(BUSINESS WIRE)–#BoothDesign–Inc., the only prominent brand focused solely on supporting owners and leaders of growing private businesses,... Read more.
ENHERTU® Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Invasive Disease-Free Survival Versus T-DM1 in DESTINY-Breast05 Phase 3 Trial in Patients with High-Risk Early Breast Cancer Following Neoadjuvant Therapy
Second positive phase 3 trial of Daiichi Sankyo and AstraZeneca’s ENHERTU in HER2 positive early breast cancer reinforces its potential to become a foundational... Read more.
Corpay and Mastercard Move Extend Near Real-Time Payments to New Markets
Corpay’s business and financial institutional clients will benefit from near-real-time payouts to 22 new markets, leveraging Mastercard Move’s extensive network.... Read more.
Visa Growth Corporates Working Capital Index Reveals Rise of the Strategic Planner and Adaptable Accelerator Shaping the Future of Liquidity Management
Corporate CFOs and Treasurers harness AI, cards and digital tools to navigate growth and volatility SAN FRANCISCO–(BUSINESS WIRE)–Visa (NYSE:V), a global... Read more.
Infobric and Stirling Square Welcome KKR as New Investor
Investment supports the acceleration of Infobric’s growth in construction software solutions JÖNKÖPING, Sweden–(BUSINESS WIRE)–Stirling Square Capital... Read more.
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
Patients who switched from placebo or pirfenidone to deupirfenidone in the open-label extension study achieved stabilization of lung function with favorable tolerability... Read more.
Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025
– The Beneficial Clinical Effects of Molgramostim Were Similar in Patients with aPAP Regardless of Disease Severity Defined by DLco% – – Changes in DLco%,... Read more.
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion... Read more.
Jumpstart Your Holiday Shopping with Prime Big Deal Days: Millions of Deals, Deep Discounts, and More Amazon-Exclusive Products in the Holiday Shop Than Ever Before
Find exceptional seasonal savings across top categories including up to 50% off select fashion from Levi’s and CIDER; up to 45% off select home products from BISSELL... Read more.
Virometix Announces Completion of Enrollment in Phase I Trial of V-212 — a Fully Synthetic, Serotype-Independent Vaccine Candidate Against Streptococcus Pneumoniae
SCHLIEREN, Switzerland–(BUSINESS WIRE)–Virometix AG, a Swiss clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced... Read more.